Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: NETs are extremely heterogeneous in nature. Despite recent advances, few biomarkers are available to consistently predict prognosis and optimize treatment selection.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Chan D, Yao J, Carnaghi C, Buzzoni R, Herbst F,
Keywords: Neuroendocrine tumors, neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, everolimus, RADIANT-3, RADIANT-4, systemic inflammation, prognosis,
Introduction: Hyperglycemia and hypercholesterolemia are class effects of mTOR inhibitors such as everolimus (EVE).
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F,
Keywords: adverse events, everolimus, RADIANT-3, RADIANT-4, landmark analysis, mTOR inhibitors, targeted therapy, neuroendocrine tumors,
Introduction: EVE showed a significant improvement of 6.4 mo in median progression-free survival (PFS) vs PBO (HR 0.35, 95% CI 0.27-0.45; P<0.001) in patients (pts) with pNET in RADIANT-3.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Yao J, Pavel M, Lombard-Bohas C, Van Cutsem E, Lam D,
Keywords: everolimus, pNET, OS,
Introduction: The RADIANT-3 trial showed Everolimus (EV), as active in patients (pts) with progressive well/intermediate grade PNETs. Intermediate/grade 2 (Ki67 3-20%) PNETs have variable biology. FDG-PET avidity is an independent negative factor for survival, consistent with aggressive disease biology- but such imaging is not used to select treatment as in the case of the RADIANT 3 trial.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Michael M, Pavlakis N, Wyld D, Link E, Liauw W,
Keywords: everolimus, FDG-PET,
Introduction: In the phase III RADIANT-3 trial, EV demonstrated a significant improvement in PFS with a median of 11.0 v. 4.6 months (mo) for placebo in pWDNETs pts.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author: pusceddu s
Authors: Pusceddu S, De Braud F, Milione M, Mazzaferro V, Damato A,
Keywords: everolimus,